430 related articles for article (PubMed ID: 36706634)
1. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.
Yang W; Wang Y; Huang Y; Yu J; Wang T; Li C; Yang L; Zhang P; Shi L; Yin Y; Tao K; Li R
Biomed Pharmacother; 2023 Mar; 159():114301. PubMed ID: 36706634
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer.
Wen H; Qu C; Wang Z; Gao H; Liu W; Wang H; Sun H; Gu J; Yang Z; Wang X
FASEB J; 2023 Sep; 37(9):e23145. PubMed ID: 37584654
[TBL] [Abstract][Full Text] [Related]
3. ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury.
Huo S; Wang Q; Shi W; Peng L; Jiang Y; Zhu M; Guo J; Peng D; Wang M; Men L; Huang B; Lv J; Lin L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675183
[TBL] [Abstract][Full Text] [Related]
4. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Zheng P; Zhou C; Lu L; Liu B; Ding Y
J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
[TBL] [Abstract][Full Text] [Related]
5. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Wang W; Lu K; Jiang X; Wei Q; Zhu L; Wang X; Jin H; Feng L
J Exp Clin Cancer Res; 2023 Jun; 42(1):142. PubMed ID: 37277863
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis.
Huang Y; Yang W; Yang L; Wang T; Li C; Yu J; Zhang P; Yin Y; Li R; Tao K
Sci Rep; 2023 Sep; 13(1):14359. PubMed ID: 37658132
[TBL] [Abstract][Full Text] [Related]
8. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function.
Li Z; Zhou H; Zhai X; Gao L; Yang M; An B; Xia T; Du G; Li X; Wang W; Jin B
Cell Death Dis; 2023 Nov; 14(11):733. PubMed ID: 37949877
[TBL] [Abstract][Full Text] [Related]
9. [Elesclomol-Cu Induces Cuproptosis in Human Acute Myeloid Leukemia Cells].
Yu YH; Li HJ; Yang XY; Yu LY; Tong XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):389-394. PubMed ID: 38660841
[TBL] [Abstract][Full Text] [Related]
10. LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma.
Quan B; Liu W; Yao F; Li M; Tang B; Li J; Ren Z; Yin X
Am J Cancer Res; 2023; 13(11):5590-5609. PubMed ID: 38058825
[TBL] [Abstract][Full Text] [Related]
11. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects.
Liao ST; Han C; Xu DQ; Fu XW; Wang JS; Kong LY
Nat Commun; 2019 Nov; 10(1):5091. PubMed ID: 31704924
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy.
Guo B; Yang F; Zhang L; Zhao Q; Wang W; Yin L; Chen D; Wang M; Han S; Xiao H; Xing N
Adv Mater; 2023 Jun; 35(22):e2212267. PubMed ID: 36916030
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: Bioinformatics analysis and experimental validation.
Li L; Cheng H; Gong L; Huang Y; Yang J; Yan Q; Dai S; Wang J
Gene; 2024 Apr; 902():148156. PubMed ID: 38211899
[TBL] [Abstract][Full Text] [Related]
14. Systemic Analyses of Cuproptosis-Related lncRNAs in Pancreatic Adenocarcinoma, with a Focus on the Molecular Mechanism of LINC00853.
Chen L; Zhang L; He H; Shao F; Gao Y; He J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175629
[TBL] [Abstract][Full Text] [Related]
15. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes.
Gao Y; Jin F; Zhang P; Zheng C; Zheng X; Xie J; Lu Y; Tong X; Du J; Zhang J; Wang Y
Biomed Pharmacother; 2024 May; 175():116727. PubMed ID: 38733771
[TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis-related gene signature to predict prognosis in Glioma.
Zhang M; Liu X; Wang D; Ruan X; Wang P; Liu L; Xue Y
BMC Cancer; 2023 Mar; 23(1):237. PubMed ID: 36915038
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
18. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis is involved in copper-induced hepatotoxicity in chickens.
Zhong G; Li L; Li Y; Ma F; Liao J; Li Y; Zhang H; Pan J; Hu L; Tang Z
Sci Total Environ; 2023 Mar; 866():161458. PubMed ID: 36621474
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
Front Immunol; 2022; 13():948042. PubMed ID: 36275737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
